scholarly article | Q13442814 |
P2093 | author name string | Liu LF | |
Grossberg H | |||
Hsiang YH | |||
Kirschenbaum S | |||
Potmesil M | |||
Bank B | |||
Kanganis D | |||
Forlenza TJ | |||
Penziner A | |||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 3537-3543 | |
P577 | publication date | 1988-06-01 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II | |
P478 | volume | 48 |
Q41396887 | "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). |
Q36614847 | A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours |
Q54291944 | Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukemic cells |
Q40388183 | Anthracycline antibiotics in cancer therapy. Focus on drug resistance |
Q55033660 | Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. |
Q36466122 | Biochemical pharmacology of anthracenediones and anthrapyrazoles |
Q36617921 | CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues |
Q40880283 | Clinical pharmacokinetics of irinotecan |
Q28343739 | Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells |
Q36135365 | Differential expression of the topoisomerase II alpha and beta genes in human breast cancers |
Q35763155 | Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. |
Q35158232 | Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer |
Q24554531 | Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin |
Q30656004 | Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data |
Q36710645 | Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. |
Q72538851 | Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features |
Q37256902 | Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast |
Q24554360 | Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL |
Q37467770 | Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. |
Q33495553 | Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration |
Q44025370 | Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy |
Q54220320 | Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. |
Q28591946 | Targeted disruption of the mouse topoisomerase I gene by camptothecin selection |
Q33500497 | The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor |
Q40028536 | Topoisomerase I inhibitors and drug resistance |
Q40694357 | Topoisomerase expression in cancer cell lines and clinical samples |
Q40499871 | Topoisomerase inhibitors. A review of their therapeutic potential in cancer |
Search more.